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Introduction {#acn3625-sec-0005}
============

The NCLs comprise 13 neurodegenerative diseases and cause blindness/neuro‐cognitive decline/spasticity/seizures and early death. Dysregulation of apoptosis,[1](#acn3625-bib-0001){ref-type="ref"} autophagy, inflammation, and galactosylceramide transport are documented.[2](#acn3625-bib-0002){ref-type="ref"}, [3](#acn3625-bib-0003){ref-type="ref"}, [4](#acn3625-bib-0004){ref-type="ref"}

Autosomal recessive inheritance predominates with some dominant CLN4 cases.[5](#acn3625-bib-0005){ref-type="ref"} CLN3 disease is the juvenile form. Infantile CLN1 disease and late infantile CLN2 disease are caused by defective palmitoyl protein thioesterase 1 (PPT1) and tripeptidyl peptidase I (TPP1), respectively. Elevated ceramide and *BCL‐2* are documented in CLN2/CLN3 disease brain.[6](#acn3625-bib-0006){ref-type="ref"} Ceramide impacts cell differentiation and growth inducing cell cycle arrest and apoptosis, all key mechanisms in neurodegenerative disorders,[1](#acn3625-bib-0001){ref-type="ref"}, [3](#acn3625-bib-0003){ref-type="ref"}, [6](#acn3625-bib-0006){ref-type="ref"} particularly CLN2/CLN3 human disease.[1](#acn3625-bib-0001){ref-type="ref"}, [7](#acn3625-bib-0007){ref-type="ref"}, [8](#acn3625-bib-0008){ref-type="ref"}, [9](#acn3625-bib-0009){ref-type="ref"} CLN3 protein downregulates ceramide.[4](#acn3625-bib-0004){ref-type="ref"}

BCL‐2 prevents cytochrome c release maintaining the electrical gradient across the mitochondrial membrane.[10](#acn3625-bib-0010){ref-type="ref"}, [11](#acn3625-bib-0011){ref-type="ref"}, [12](#acn3625-bib-0012){ref-type="ref"} Cytochrome c bound to apoptosis protease activating factor (APAF1) activates caspases 8/9/caspase 3 causing cell death.[13](#acn3625-bib-0013){ref-type="ref"}

Flupirtine, a nonopioid analgesic, upregulates *BCL‐2,* protects postmitotic neurons from death by increasing glutathione, activating G protein inwardly rectifying potassium channels, delaying calcium loss within the intermitochondrial membrane space and also possesses muscle‐relaxant/anticonvulsant properties beneficial in NCL.[14](#acn3625-bib-0014){ref-type="ref"} Flupirtine protects neuronal/photoreceptor cells/normal/CLN1/CLN2/CLN3 and CLN6‐deficient lymphoblasts from etoposide‐induced apoptosis.[14](#acn3625-bib-0014){ref-type="ref"}

Intrathecal injection of TPP1 slows down CLN2 disease in mice[15](#acn3625-bib-0015){ref-type="ref"}, [16](#acn3625-bib-0016){ref-type="ref"} and humans. Flupirtine and aromatic carbamate derivatives[17](#acn3625-bib-0017){ref-type="ref"} antiapoptotic properties provide the basis for use as potential therapies in NCL disease.

Methods {#acn3625-sec-0006}
=======

Tissue culture {#acn3625-sec-0007}
--------------

Immortalized lymphoblasts from normal controls/patients with defects in *CLN1*/2/3/6/8 genes were used. Use of patient cells is approved by an American University of Beirut Medical Center (AUBMC) University Institutional Review Board protocol. Lymphoblasts are grown at 37°C in a humidified atmosphere, 5% CO~2~/95% air in RPMI 1640 medium (Lonza) supplemented with 10% heat‐inactivated fetal bovine serum (FBS) (Sigma), 1X Gentamycin (Sigma), and 1% penicillin/streptomycin (Lonza). PC12 neuronal precursor cells are maintained at 37°C in a humidified atmosphere, 5% CO~2~/95% air in DMEM medium (Lonza) supplemented with 10% heat‐inactivated horse serum (Sigma), 5% heat‐inactivated FBS (Sigma), 1% Sodium pyruvate (Lonza), and 1% penicillin/streptomycin (Lonza). Medium is changed every 2 days, and cells split weekly.

siRNA CLN3 knockdown in PC12 cells {#acn3625-sec-0008}
----------------------------------

PC‐12 cells are transfected with siRNA for *CLN3* knock‐down (BLOCK‐iT RNA^™^ Designer, Invitrogen)/scrambled control (HiPerfect Transfection, Qiagen). *CLN3* knockdown is validated by quantitative real‐time PCR (qRT‐PCR) at 24/48/72 h, and normalized to *β‐actin*. Expression levels are calculated using the ΔΔC~T~ method. Primer sequences (Tm = 60^○^C) include: CLN3 forward, 5′AGACCCTCATCCCTCCCGT3′; reverse, 5′GAATCCGAAAAGCGCCGCC3′; *β*‐Actin forward, 5′ACACTGTGCCCATCTACGAG3′; reverse, 5′ATTTCCCTCTCAGCTGTGGT3′.

Treatment with flupirtine/aromatic carbamate derivatives {#acn3625-sec-0009}
--------------------------------------------------------

A total of 24 h after seeding, cells are treated with 20 *μ*mol/L flupirtine dissolved in 0.004% ethanol (Vehicle 1); 20 or 50 *μ*mol/L retigabine dissolved in 0.1% DMSO (Vehicle 3); 20 *μ*mol/L methyl carbamate analog (compound 3) dissolved in 0.004% ethanol (Vehicle 1); 20 or 50 *μ*mol/L isobutyl carbamate derivative (compound 4) dissolved in 0.004% ethanol (Vehicle 1); 3, 20 or 50 *μ*mol/L benzyl‐derivatized carbamate (compound 5) dissolved in 0.07% DMSO (Vehicle 2); 3, 20 or 50 *μ*mol/L allyl carbamate derivative (compound 6) dissolved in 0.07% DMSO (Vehicle 2); 20 or 50 *μ*mol/L *tert*‐butyl carbamate derivative (compound 7) dissolved in 0.1% DMSO (Vehicle 3); 20 or 50 *μ*mol/L carbamate derivative with substitution of chlorine at the *para* position (compound 8) dissolved in 0.004% ethanol (Vehicle 1); 20 or 50 *μ*mol/L 1‐chloroethyl analog (compound 9) dissolved in 0.004% ethanol (Vehicle 1); 0.1, 1 or 10 *μ*mol/L 4‐trifluoromethyl derivative (compound 10) dissolved in 0.004% ethanol (Vehicle 1); or with the corresponding vehicle. After 4 h, cells are washed, centrifuged (only for lymphoblasts) and fresh media added.

Cell growth/Viability by trypan blue dye exclusion {#acn3625-sec-0010}
--------------------------------------------------

1.5 × 10^5^ PC12 cells are seeded/well and treated with 10 *μ*g/mL etoposide (Sigma) for 18 h or transfected with *CLN3* or scrambled siRNA for 24 h. 1.5 × 10^5^ normal/patient‐derived lymphoblast cells (CLN1/2/3/6/8) are seeded/well. 24 h later, cells are washed, centrifuged and media containing compound is added. 4 h later, cells are washed, centrifuged and fresh media is added. 24 h later, cells are stained with trypan blue dye (0.4%) and white (viable) and blue (dead) cells counted at 24/48/72 h in triplicate using a light microscope and a hemocytometer.

Propidium Iodide (PI) staining {#acn3625-sec-0011}
------------------------------

1 × 10^5^ PC12 cells, treated with 10 *μ*g/mL etoposide (Sigma)/vehicle for 18 h, are grown on coverslips, then washed, centrifuged and media containing compound added. 4 h later, cells are washed, centrifuged and media added. 24 h later, cells are stained with PI (5*μ*g/mL) for 5 min. Three fields of vision are chosen randomly. Total number of cells/field of vision are counted. Number of PI‐positive red apoptotic cells is determined under fluorescence, and percentage of PI‐positive cells/total cells/field of vision calculated.

JC‐1 Staining {#acn3625-sec-0012}
-------------

JC‐1 stain (5,50--60‐tetrachloro‐1,1,3,3‐tetraethylbenzimidazolylcarbocyanine iodide; Molecular Probes, Eugene, OR) assesses decrease in mitochondrial membrane potential after treatment with compounds. This dye forms J‐aggregates with cytochrome *c*‐APAF‐1 complex. Onset of apoptosis is visualized with shift in emission from red (595 nm) to green (535 nm). 5x10^4^ normal/patient lymphoblasts (CLN1/2/3/6/8) are grown/well in triplicate. Then, cells are washed, centrifuged, and media containing compound added. 4 h later, cells are washed, centrifuged and media added. 24 h later, cells are incubated with 200 *μ*mol/L of JC‐1 stain at 37°C for 30 min. Samples are analyzed by a fluorescent plate reader. In healthy cells, JC‐1 forms J‐aggregates which display strong red fluorescent intensity with excitation/emission at 560 nm and 595 nm, respectively. In apoptotic cells, JC‐1 exists as monomers exhibiting strong green fluorescence with excitation and emission at 485 nm and 53 nm. Ratio of fluorescence of J‐aggregates (red) to monomers (green) is used as an indicator of cell death.

Ceramide levels {#acn3625-sec-0013}
---------------

### Cell Homogenization {#acn3625-sec-0014}

Cell pellets are washed with ice‐cold PBS, suspended in methanol/chloroform (2:1) and stored at −80°C for 48--36 h.

### Lipid Extraction {#acn3625-sec-0015}

A total of 700 *μ*L of distilled water are added to the homogenate, then 1 mL chloroform and 1 mL of distilled water, and the sample centrifuged at 956 ×g for 10 min at 4°C. The lower phase is lyophilized. Lipids are resuspended in 1 mL chloroform.

### Ceramide Assay (Diacyl glycerol kinase (DGK) assay) {#acn3625-sec-0016}

Ceramide standards (Non‐hydroxy Fatty Acid Ceramide from Sigma‐Aldrich) and samples were dried under vacuum. *β‐*octylglucoside (BOG) (Sigma‐Aldrich) and 1,2‐dioleoyl‐sn‐glycero‐3‐phospho‐(1′‐rac‐glycerol) (DOPG) (Sigma‐Aldrich) were added as micelles mixture to samples/standards and sonicated for 30 min. Reaction mixtures were added to the ATP mix containing 1.3 *μ*Ci ATP, \[*γ*‐^32^P\] (IZOTOP) per sample and incubated at room temperature (RT) for 45 min. The reaction was stopped using methanol/chloroform/distilled water prior to lipid extraction. Lower phase is dried under vaccum, resuspended in chloroform/methanol (9:1) and run on a TLC plate (SILICYCLE) using chloroform/acetone/methanol/acetic acid/water as running buffer (50:20:15:10:5). Plates were dried, x‐ray film overlaid and kept at −80°C overnight to visualize ceramide bands. Lanes of the TLC plate are scraped into scintillation vials, and counts/minute detected using a liquid scintillation counter. Results are expressed as pmols of ceramide/nmol of total phospholipids.

### Phosphate determination {#acn3625-sec-0017}

After lyophilization, 150 *μ*L of 70% perchloric acid (Fluka) were added to disodium hydrogen phosphate (Na~2~HPO~4~) (MERCK) standards. Tubes were capped with methanol‐soaked glass balls, placed at 180°C for 1 h, cooled at RT, and distilled water/2.5% ammonium molybdate (Riedel‐de Haën)/10% ascorbic acid (Biochemical) added. Mixtures were incubated for 15 min at 50°C, and concentration determined spectrophotometerically (820 nm wavelength).

RNA isolation {#acn3625-sec-0018}
-------------

Using RIBOZOL^™^ (AMRESCO), total RNA is isolated from cells, according to manufacturer protocols and stored at −80°C. RNA quality is assessed by analyzing A~260~/A~280~ and A~260~/A~230~ ratios with a ND‐1000 spectrometer (Nanodrop Technologies).

qRT‐PCR {#acn3625-sec-0019}
-------

Total RNA is reverse‐transcribed using RevertAid Reverse Transcriptase (Thermo Scientific) with 1000 ng of input RNA and random primers (Thermo Scientific). qRT‐PCR reactions are performed using specific primers (TIB MOLBIOL) and the iQ^™^ SYBR^®^ Green Supermix (BioRad) as fluorescent detection dye, in CFX96^™^ Real‐Time PCR (BioRad), in 12.5 *μ*L in duplicate. To characterize generated amplicons and to control contamination by unspecific by‐products, melt curve analysis is performed. Results are normalized to *β‐actin* and expression levels calculated using ΔΔC~t~ method. Primer sequences (Tm = 60°C): SMPD1 forward, 5′CTATGAAGCGATGGCCAAG3′; reverse, 5′TGGGGAAAGAGCATAGAACC3′; CerS2 forward, 5′GCTGGAGATTCACATTTTACC3′; reverse, 5′CGAAGACGATGAAGATGTTGT3′; CerS6 forward, 5′TTTAGGGCACAGTTCTTTGG3′; reverse, 5′ACAGGGGGAGGATGAGATAC3′; DEGS2 forward, 5′GACTTCGAGTGGGTCTACAC3′; reverse, 5′GGTCCACGTGGTACTTCTTG3′; BCL‐2 forward, 5′TGTGTGTGGAGAGCGTCAAC3′; reverse, 5′TGAGCAGAGTCTTCAGAGAC3′; Caspase 3 forward, 5′TGGTTCATCCAGTCGCTTTG3′; reverse, 5′CATTCTGTTGCCACCTTTCG3′; Caspase 8 forward, 5′CTGCTGGGGATGGCCACTGTG3′; reverse, 5′TCGCCTCGAGGACATCGCTCTC3′; Caspase 9 forward, 5′CGAACTAACAGGCAAGCAGC3′; reverse, 5′ACCTCACCAAATCCTCCAGAAC3′; *β*‐Actin forward, 5′ACACTGTGCCCATCTACGAG3′; reverse, 5′ATTTCCCTCTCAGCTGTGGT3′.

Statistical analysis {#acn3625-sec-0020}
--------------------

Continuous data were expressed as means ± SEM, and compared by two‐tailed Student\'s *t‐*test and one‐way ANOVA followed by posthoc tests.

GraphPad Prism 6 (GraphPad Software, Inc., California, USA) was used. All tests were two‐sided and *P* \< 0.05 was considered as statistically significant.

Results {#acn3625-sec-0021}
=======

Flupirtine/aromatic carbamate derivatives positively modulate growth and protect PC12 cells from etoposide‐induced apoptosis {#acn3625-sec-0022}
----------------------------------------------------------------------------------------------------------------------------

Flupirtine and flupirtine analogues (Fig. [1](#acn3625-fig-0001){ref-type="fig"}A) enhanced growth and protected neuronal precursor PC12 cells from apoptosis induced by etoposide. The degree of protection was variable depending on the carbamate used. Treatment with 20 *μ*mol/L flupirtine exhibited slightly enhanced growth at 24 h compared to vehicle‐treated PC12 cells, when cells were pretreated with etoposide (Fig. [1](#acn3625-fig-0001){ref-type="fig"}B). The benzyl‐derivatized carbamate (compound 5) and the allyl carbamate derivative (compound 6) were significantly protective after addition of etoposide to PC12 cells, based on trypan blue dye exclusion (data not shown). Treatment with benzyl‐derivatized carbamate (compound 5) at 50 *μ*mol/L resulted in significantly increased cell growth compared with vehicle‐treated PC12 cells after etoposide (Fig. [1](#acn3625-fig-0001){ref-type="fig"}C, asterisk symbol). Similarly, treatment with allyl carbamate derivative (compound 6) at 20 *μ*mol/L caused significantly increased cell growth compared with vehicle‐treated PC12 cells treated with etoposide (Fig. [1](#acn3625-fig-0001){ref-type="fig"}D, asterisk symbol). Treatment with 20 *μ*mol/L retigabine conferred significant protection against etoposide‐induced apoptosis compared with vehicle‐treated PC12 cells, at 24 h (Fig. [1](#acn3625-fig-0001){ref-type="fig"}E, asterisk symbol). This protection was confirmed by PI staining whereby flupirtine/compound 5/6 and retigabine significantly decreased, in equal manner, total number of dead cells compared to vehicle‐treated PC12 cells after etoposide treatment (Fig. [1](#acn3625-fig-0001){ref-type="fig"}F, † symbol).

![Treatment with flupirtine, retigabine, the benzyl (compound 5) or allyl (compound 6) carbamate derivatives enhances cell growth and decreases apoptosis in etoposide‐treated PC12 neuronal precursor cells. (A) Chemical structure of flupirtine and aromatic carbamate derivatives. Growth curve of PC12 neuronal precursor cells treated with etoposide and in response to treatment with (B) 20 *μ*mol/L flupirtine, (C) 50 *μ*mol/L compound 5, (D) 20 *μ*mol/L compound 6, or (E) 20 *μ*mol/L retigabine. Live cells are counted in triplicate at time‐points 0, 24, 48, and 72 h. (F) Propidium Iodide staining of PC12 neuronal precursor cells treated with etoposide in response to treatment with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, 20 *μ*mol/L compound 6, or 20 *μ*mol/L retigabine. These drugs increase growth and decrease the number of PI‐positive apoptotic cells compared to vehicle‐treated PC12 neuronal precursor cells (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, and \*\*\*\**P* \< 0.0001). Flupirtine is compared to vehicle 1, benzyl (compound 5), and allyl (compound 6) carbamate derivatives are compared to vehicle 2, and retigabine is compared to vehicle 3. Results in panels B to E represent the mean ± SEM of three‐independent experiments analyzed by multiple *t*‐tests with Holm--Sidak correction to determine statistical significance, with alpha=0.05 (asterisk symbol). Results in panel F represent the mean ± SEM of three‐independent experiments analyzed by one‐way ANOVA (alpha = 0.05) followed by Sidak\'s posthoc multiple comparisons († symbol) ^†††^ *P* \< 0.001 and ^††††^ *P* \< 0.0001.](ACN3-5-1089-g001){#acn3625-fig-0001}

Flupirtine/aromatic carbamate derivatives rescue PC12 cells from CLN3‐knockdown apoptosis {#acn3625-sec-0023}
-----------------------------------------------------------------------------------------

PC12 cells demonstrated significant growth inhibition when cells were transfected with siRNA against *CLN3* versus scrambled siRNA, at 24 h showing maximum *CLN3* knockdown of 75% (*P* \< 0.001) (Fig. [2](#acn3625-fig-0002){ref-type="fig"}A). Treatment with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, 20 *μ*mol/L compound 6, and 20 *μ*mol/L retigabine resulted in significant increase in growth in si*CLN3*‐transfected PC12 cells compared to vehicle‐treated si*CLN3*‐transfected PC12 cells (Fig. [2](#acn3625-fig-0002){ref-type="fig"}B, asterisk symbol). Cell growth was significantly higher after treatment with compounds 5/6 compared to flupirtine and retigabine treatment (Fig. [2](#acn3625-fig-0002){ref-type="fig"}B, † symbol).

![Treatment with flupirtine, retigabine, the benzyl (compound 5) or allyl (compound 6) carbamate derivatives corrects growth and decreases apoptosis in CLN3‐deficient PC12 neuronal precursor cells and in CLN1/CLN2/CLN3/CLN6/CLN8 patient‐derived lymphoblast cells. (A) Maximum si*CLN3* knock‐down in PC12 cells is determined by qRT‐PCR. Relative *CLN3* mRNA/*PGK1* (%) of PC12 transfected cells with si*CLN3* at 24, 48, and 72 h compared to scrambled siRNA. (B) Growth curve of PC12 neuronal precursor cells transfected with siCLN3 for 24 h and (C) CLN1/(D) CLN2/(E) CLN3/(F) CLN6/(G) CLN8‐derived lymphoblast cell lines treated with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, 20 *μ*mol/L compound 6, or 20 *μ*mol/L retigabine. Live cells are counted in triplicate at 24 h. (A) CLN3‐deficient PC12 cells treated with flupirtine (\**P* \< 0.05), compound 5 (\**P* \< 0.05), compound 6 (\**P* \< 0.05), and retigabine (\*\**P* \< 0.01) exhibit an increase in number of live cells compared to vehicle‐treated cells. (C) Treatment with compound 6 and retigabine significantly increases cell growth compared to vehicle‐treated CLN1‐derived lymphoblast cell lines (\**P* \< 0.05). (D) Treatment with compound 6 (\*\**P* \< 0.01) and retigabine (\**P* \< 0.05) significantly increases cell growth compared with vehicle‐treated CLN2‐derived lymphoblast cells. (E) Treatment with compound 6 and retigabine significantly increases the percentage of live cells compared to vehicle‐treated CLN3‐derived lymphoblast cells (\**P* \< 0.05). (F) Treatment with compounds 5 and 6 and retigabine significantly increases number of live cells compared to vehicle‐treated CLN6‐derived lymphoblast cells (\**P* \< 0.05). (G) Treatment with flupirtine (\*\**P* \< 0.01), compound 5 (\**P* \< 0.05), compound 6 (\*\**P* \< 0.01) and retigabine (\**P* \< 0.05) significantly increases the percentage of live cells compared to vehicle‐treated CLN8‐derived lymphoblast cells. Flupirtine is compared to vehicle 1, the benzyl (compound 5) and allyl (compound 6) carbamate derivatives are compared to vehicle 2, and retigabine is compared to vehicle 3. Results represent the mean ± SEM of three‐independent experiments analyzed by Student\'s *t*‐test when comparing each compound to its vehicle (asterisk symbol) and by one‐way ANOVA (alpha = 0.05) followed by Tukey\'s posthoc multiple comparisons when comparing all compounds among each other († symbol) ^†^ *P* \< 0.05, ^††^ *P* \< 0.01, and ^†††^ *P* \< 0.001.](ACN3-5-1089-g002){#acn3625-fig-0002}

Flupirtine/aromatic carbamate derivatives block apoptosis selectively in CLN1/2/3/6/8‐derived lymphoblasts {#acn3625-sec-0024}
----------------------------------------------------------------------------------------------------------

Treatment of CLN1/2/3/6/8‐derived lymphoblasts with flupirtine, retigabine, and aromatic carbamate derivatives enhances cell growth (Fig. [2](#acn3625-fig-0002){ref-type="fig"}C--G, asterisk symbol). Degree of protection was compound‐specific and disease cell line‐dependent. Treatment with 20 *μ*mol/L flupirtine significantly enhanced growth in CLN8‐derived lymphoblasts compared to vehicle‐treated cells. Treatment with benzyl‐derivatized carbamate (compound 5) at 50 *μ*mol/L improved growth significantly compared to growth of vehicle‐treated CLN6/8‐derived patient lymphoblasts. Treatment with allyl carbamate derivative (compound 6) at 20 *μ*mol/L exhibited significant increase in growth compared to vehicle‐treated CLN1/2/3/6/8‐derived patient lymphoblasts. Similarly, treatment with 20 *μ*mol/L retigabine conferred significant protection against apoptosis compared to corresponding vehicle‐treated patient cell lines. In CLN1/CLN8‐derived lymphoblasts, cell growth was significantly higher after treatment with compound 6 compared to other compounds (Fig. [2](#acn3625-fig-0002){ref-type="fig"}C and G, † symbol).

This protection was confirmed by JC‐1 staining of compound versus vehicle‐treated CLN1/2/3/6/8‐derived lymphoblasts (Fig. [3](#acn3625-fig-0003){ref-type="fig"}A--E, asterisk symbol). Treatment of patient lymphoblasts with 20 *μ*mol/L flupirtine resulted in a significant reduction in number of apoptotic cells with J‐aggregates compared with vehicle‐treated cells, suggesting that flupirtine rescues CLN1‐ (*P* \< 0.05), CLN2‐ (*P* \< 0.01), CLN3‐ (*P* \< 0.05), CLN6‐ (*P* \< 0.01), and CLN8‐derived (*P* \< 0.01) patient lymphoblasts from apoptosis. Treatment of patient lymphoblasts with compound 5 (50 *μ*mol/L) reduced the number of apoptotic cells with J‐aggregates compared to vehicle‐treated cells. This was significant in CLN2‐ (*P* \< 0.05)/CLN8‐derived (*P* \< 0.05) patient lymphoblasts. Treatment of patient lymphoblasts with compound 6 (20 *μ*mol/L) significantly reduced the number of apoptotic cells with J‐aggregates compared to vehicle‐treated cells in CLN1‐ (*P* \< 0.05), CLN2‐ (*P* \< 0.01), CLN3‐ (*P* \< 0.05), CLN6‐ (*P* \< 0.05), and CLN8‐derived (*P* \< 0.05) patient lymphoblasts. Treatment of patient lymphoblasts with retigabine (20 *μ*mol/L) resulted in significant reduction in the number of apoptotic cells with J‐aggregates compared to vehicle‐treated CLN1‐ (*P* \< 0.05), CLN2‐ (*P* \< 0.05), CLN3‐ (*P* \< 0.05), CLN6‐ (*P* \< 0.05), and CLN8‐derived (*P* \< 0.01) patient lymphoblasts. In CLN1‐derived lymphoblasts, rescue from apoptosis was significantly higher after flupirtine compared to other compounds (Fig. [3](#acn3625-fig-0003){ref-type="fig"}A, † symbol). In CLN2‐derived lymphoblasts, rescue from apoptosis was significantly higher after treatment with compound 6 compared to others (Fig. [3](#acn3625-fig-0003){ref-type="fig"}B, † symbol).

![Treatment with flupirtine, retigabine, benzyl (compound 5), or allyl (compound 6) carbamate derivatives decreases apoptosis in CLN1/CLN2/CLN3/CLN6/CLN8 patient‐derived lymphoblast cells. JC‐1 staining of (A) CLN1/(B) CLN2/(C) CLN3/(D) CLN6/(E) CLN8‐derived lymphoblast cell lines treated with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, 20 *μ*mol/L compound 6, or 20 *μ*mol/L retigabine. (A) Treatment with flupirtine, compound 6 and retigabine significantly decreases the number of apoptotic cells compared to apoptotic cells in corresponding vehicle‐treated CLN1‐derived lymphoblast cell lines (\**P* \< 0.05). (B) Treatment with flupirtine (\*\**P* \< 0.01), compound 5 (\**P* \< 0.05), compound 6 (\*\**P* \< 0.01), and retigabine (\**P* \< 0.05) significantly decreases the number of apoptotic cells compared to corresponding vehicle‐treated CLN2‐derived lymphoblast cell lines. (C) Treatment with flupirtine, compound 6 and retigabine significantly decreases the number of apoptotic cells compared to corresponding vehicle‐treated CLN3‐derived lymphoblast cell lines (\**P* \< 0.05). (D) Treatment with flupirtine (\*\**P* \< 0.01), compound 6 (\**P* \< 0.05) and retigabine (\**P* \< 0.05) significantly decreases the number of apoptotic cells compared with apoptotic cells in corresponding vehicle‐treated CLN6‐derived lymphoblast cell lines. (E) Treatment with flupirtine (\*\**P* \< 0.01), compound 5 (\**P* \< 0.05), compound 6 (\**P* \< 0.05) and retigabine (\*\**P* \< 0.01) significantly decreases the number of apoptotic cells compared to corresponding vehicle‐treated CLN8‐derived lymphoblast cell lines. Flupirtine is compared to vehicle 1, the benzyl (compound 5) and allyl (compound 6) carbamate derivatives are compared to vehicle 2, and retigabine is compared to vehicle 3. Results represent the mean ± SEM of three‐independent experiments analyzed by Student\'s *t*‐test when comparing each compound to its vehicle (asterisk symbol) and by one‐way ANOVA (alpha = 0.05) followed by Tukey\'s posthoc multiple comparisons when comparing all compounds among each other († symbol) ^†^ *P* \< 0.05, ^†††^ *P* \< 0.001, and ^††††^ *P* \< 0.0001.](ACN3-5-1089-g003){#acn3625-fig-0003}

Flupirtine/aromatic carbamate derivatives impact ceramide signaling pathways in PC12 cells and CLN1/2/3/6/8‐derived lymphoblasts {#acn3625-sec-0025}
--------------------------------------------------------------------------------------------------------------------------------

Ceramide levels are elevated in CLN3 disease patient sera (El‐Sitt et al., Elevated ceramide levels in CLN3 patients and *Cln3* ^*Δex7/8*^ mice and developmental comparison between wild type and Cln3^Δex7/8^ mouse sera and brain, submitted to Pediatric Research), cells, and brain.[3](#acn3625-bib-0003){ref-type="ref"} The level of ceramide in CLN1/2/3/6/8‐derived lymphoblast cell lines is significantly higher than level in normal lymphoblasts (Fig. [4](#acn3625-fig-0004){ref-type="fig"}A, asterisk symbol). Level of ceramide in CLN6/CLN8‐derived lymphoblasts is significantly higher than level in CLN1‐derived lymphoblasts (Fig. [4](#acn3625-fig-0004){ref-type="fig"}A, † symbol).

![Ceramide levels in normal and CLN1/CLN2/CLN3/CLN6/CLN8 patient‐derived lymphoblast cells treated with flupirtine, benzyl (compound 5), or allyl (compound 6) carbamate derivatives. (A) Measurement of ceramide levels in CLN1‐, CLN2‐, CLN3‐, CLN6‐ and CLN8‐derived lymphoblast cells compared to normal lymphoblasts. Results represent the mean ± SEM of five independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 by Student\'s *t*‐test as compared to normal lymphoblasts. Ceramide levels of (B) CLN1/(C) CLN2/(D) CLN3/(E) CLN6/(F) CLN8‐derived lymphoblast cells treated with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, or 20 *μ*mol/L compound 6. Treatment with drugs decreases ceramide levels compared to levels in corresponding vehicle‐treated CLN1/CLN2/CLN3/CLN6/CLN8 patient‐derived lymphoblast cells. Results in panel A represent the mean ± SEM of three‐independent experiments analyzed by Student\'s *t*‐test when comparing each CLN‐deficient lymphoblast cell line to the normal lymphoblasts (asterisk symbol) and by one‐way ANOVA (alpha = 0.05) followed by Tukey\'s posthoc multiple comparisons when comparing all cell lines among each other († symbol). Results in panels B to F represent the mean ± SEM of three‐independent experiments analyzed by Student\'s *t*‐test when comparing each compound to the vehicle (asterisk symbol) and by one‐way ANOVA (alpha = 0.05) followed by Tukey\'s posthoc multiple comparisons when comparing all compounds among each other († symbol) ^†^ *P* \< 0.05.](ACN3-5-1089-g004){#acn3625-fig-0004}

Flupirtine significantly decreases level of ceramide in CLN1‐derived lymphoblasts versus ceramide in vehicle‐treated cells. Similarly, flupirtine decreases ceramide levels in CLN2‐ and CLN3‐lymphoblasts versus ceramide in vehicle‐treated cells. This decrease was not statistically significant. Although in CLN6‐ (*P*‐value = 0.08) and CLN8‐lymphoblasts (*P*‐value = 0.06), the decrease in ceramide levels trended toward significance, but was not statistically significant. Benzyl‐derivatized carbamate (compound 5) significantly decreases ceramide in CLN1‐, CLN2‐, and CLN8‐derived lymphoblasts compared to ceramide in vehicle‐treated cells. In CLN3‐ (*P*‐value = 0.55) and CLN6‐derived lymphoblasts (*P*‐value = 0.12), decrease in ceramide by compound 5 trended toward significance, but was not statistically significant. Treatment with allyl carbamate derivative (compound 6) significantly decreases ceramide in CLN1‐ and CLN8‐lymphoblasts versus ceramide in vehicle‐treated cells. In CLN2‐ and CLN3‐derived lymphoblasts, decrease in ceramide by compound 6 was not significant. Although in CLN6‐derived lymphoblasts, the decrease in ceramide levels trended toward significance, but was not statistically significant (*P*‐value = 0.08) (Fig. [4](#acn3625-fig-0004){ref-type="fig"}B--F, asterisk symbol).

Flupirtine/aromatic carbamate derivatives regulate expression of Bcl‐2, caspases 3/8/9 {#acn3625-sec-0026}
--------------------------------------------------------------------------------------

*CLN3* knockdown of 75% (*P* \< 0.001) was determined at 24 h (Fig. [2](#acn3625-fig-0002){ref-type="fig"}A). Transfection of PC12 cells with siRNA against *CLN3* for 24 h causes a significant decrease in expression of *BCL‐2* compared to scrambled siRNA‐treated cells (Fig. [5](#acn3625-fig-0005){ref-type="fig"}A, asterisk symbol). Treatment with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, or 20 *μ*mol/L compound 6 significantly upregulated, in equal manner, *BCL‐2* expression versus vehicle‐treated si*CLN3*‐transfected cells. Blocking *CLN3* expression significantly increased *Caspases 3/8/9* expression versus scrambled siRNA‐treated cells (Fig. [5](#acn3625-fig-0005){ref-type="fig"}B--D, asterisk symbol). Flupirtine/compounds 5/6 significantly downregulated *Caspases 3/8* expression versus vehicle‐treated si*CLN3*‐transfected cells (Fig. [5](#acn3625-fig-0005){ref-type="fig"}B and C, asterisk symbol). *Caspase 9* expression was significantly reduced in flupirtine‐/compound 5‐treated cells versus vehicle‐treated si*CLN3*‐transfected cells (Fig. [5](#acn3625-fig-0005){ref-type="fig"}D, asterisk symbol). *Caspase 3/9* downregulation was significantly higher after treatment with flupirtine and compound 5 versus compound 6 (Fig. [5](#acn3625-fig-0005){ref-type="fig"}B and D, † symbol). *Caspase 8* downregulation was significantly higher after treatment with compounds 5/6 compared to flupirtine treatment (Fig. [5](#acn3625-fig-0005){ref-type="fig"}C, † symbol).

![Expression of *BCL‐2, Caspases 3, 8 and 9* in CLN3‐deficient PC12 neuronal precursor cells. Maximum si*CLN3* knock‐down in PC12 cells shown in Fig [2](#acn3625-fig-0002){ref-type="fig"}A. PC12 neuronal precursor cells are transfected with si*CLN3* for 24 h and treated with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, or 20 *μ*mol/L compound 6. Total RNA is extracted and quantitative real‐time PCR experiments performed using specific primers for (A) *BCL‐2*, (B) *Caspase 3*, (C) *Caspase 8* and (D) *Caspase 9*. Values are means of the fold change normalized to *β‐Actin* mRNA expression, with standard errors of the mean (SEM) represented by vertical bars. Transfection of neuronal precursor PC12 cells with si*CLN3* decreases *BCL‐2* (\*\*\**P* \< 0.001) and increases *Caspase 3* (\*\**P* \< 0.01), *Caspase 8* (\*\*\*\**P* \< 0.0001) and *Caspase 9* (\*\**P* \< 0.01) expression compared to transfection with scrambled siRNA. Treatment with flupirtine, compounds 5 and 6 increases *BCL‐2* levels and decreases levels of *Caspases 3, 8* and *9*. Results represent the mean ± SEM of three‐independent experiments analyzed by Student\'s *t*‐test when comparing all bars to the vehicle bar (asterisk symbol) and by one‐way ANOVA (alpha = 0.05) followed by Tukey\'s posthoc multiple comparisons when comparing all compounds among each other († symbol) ^†^ *P* \< 0.05, ^††^ *P* \< 0.01 and ^†††^ *P* \< 0.001.](ACN3-5-1089-g005){#acn3625-fig-0005}

Flupirtine/aromatic carbamate derivatives regulate expression of ceramide synthesis enzymes {#acn3625-sec-0027}
-------------------------------------------------------------------------------------------

To evaluate the molecular effects of flupirtine and aromatic carbamate derivatives on ceramide synthetic pathways, expression levels of ceramide synthesis enzymes, including ceramide synthase 2 (*CERS2),* ceramide synthase 6 *(CERS6),* acidic sphingomyelinase *(SMPD1),* and delta(4)‐desaturase sphingolipid 2 (*DEGS2)* were analyzed. Maximum *CLN3* knockdown of 75% (*P* \< 0.001) was determined at 24 h (Fig. [2](#acn3625-fig-0002){ref-type="fig"}A). Blocking *CLN3* expression by siRNA for 24 h increases pro‐apoptotic ceramide[9](#acn3625-bib-0009){ref-type="ref"}, [18](#acn3625-bib-0018){ref-type="ref"} and significantly upregulates expression of ceramide synthesis enzymes *CERS2, CERS6, SMPD1*, and *DEGS2* compared to expression in scrambled siRNA controls. Addition of flupirtine, compound 5/6 attenuated, in equal manner *CERS2/CERS6, SMPD1/DEGS2* expression versus expression in vehicle‐treated si*CLN3*‐transfected cells (Figs. [6](#acn3625-fig-0006){ref-type="fig"}A--D, asterisk symbol).

![Expression of ceramide synthesis enzymes (*CERS2, CERS6, SMPD1* and *DEGS2*) in CLN3‐deficient PC12 neuronal precursor cells. Maximum si*CLN3* knock‐down in PC12 cells shown in Fig [2](#acn3625-fig-0002){ref-type="fig"}A. PC12 neuronal precursor cells are transfected with siCLN3 for 24 h and treated with 20 *μ*mol/L flupirtine, 50 *μ*mol/L compound 5, or 20 *μ*mol/L compound 6. Total RNA is extracted and quantitative real‐time PCR performed using specific primers for (A) *CERS2*, (B) *CERS6*, (C) *SMPD1* and (D) *DEGS2* cDNA. Values are means of the fold change normalized to *β‐Actin* mRNA expression, with standard errors of the mean (SEM) represented by vertical bars. Transfection of neuronal precursor PC12 cells with siCLN3 increases *CERS2* (\*\**P* \< 0.01), *CERS6* (\*\**P* \< 0.01), *SMPD1* (\*\*\*\**P* \< 0.0001) and *DEGS2* (\*\*\**P* \< 0.001) expression levels as compared to scrambled siRNA. Treatment with flupirtine, compounds 5 and 6 decreases the levels of *CERS2*,*CERS6*,*SMPD1* and *DEGS2*. Results represent the mean ± SEM of three‐independent experiments analyzed by Student\'s *t*‐test when comparing all bars to the vehicle bar (asterisk symbol) and by one‐way ANOVA (alpha = 0.05) followed by Tukey\'s posthoc multiple comparisons when comparing all compounds among each other († symbol).](ACN3-5-1089-g006){#acn3625-fig-0006}

Discussion {#acn3625-sec-0028}
==========

The NCLs are fatal disorders. Intrathecal TPP1 is effective in slowing disease in CLN2 disease, but is expensive and medical coverage available only in few countries. Gene and/or protein replacement are not options for NCLs due to defective membrane proteins (CLN3/CLN6/CLN8), hence the need for alternate novel therapies accessible to all.[19](#acn3625-bib-0019){ref-type="ref"} Flupirtine is neuroprotective in human postmitotic neurons and photoreceptors.[14](#acn3625-bib-0014){ref-type="ref"} The significant protection flupirtine imparts to CLN1/2/3/8‐derived lymphoblasts, as well as CLN2/3‐deficient postmitotic human‐derived neurons provides the basis for use in some NCLs.[14](#acn3625-bib-0014){ref-type="ref"} Flupirtine is a derivative of triaminopyridine in the form of ethyl‐*N*‐\[2‐amino‐6‐(4‐fluorophenylmethylamino) pyridin‐3‐yl\]carbamate (Fig. [1](#acn3625-fig-0001){ref-type="fig"}A). The carbamate group is cleavable under strong basic and acid conditions.[20](#acn3625-bib-0020){ref-type="ref"} Retigabine, a phenyl bioisostere of flupirtine, is approved for use as an anticonvulsant and analgesic drug. Flupirtine penetrates the blood‐brain barrier. Retigabine exerts neuroprotective properties in vitro in rat organotypic hippocampal slice cultures exposed to oxygen, glucose deprivation, and serum withdrawal.[21](#acn3625-bib-0021){ref-type="ref"} Efficacy of flupirtine on cognitive function in Creutzfeldt‐Jakob disease patients is reported.[22](#acn3625-bib-0022){ref-type="ref"} Flupirtine and retigabine may be promising drugs for treatment of Alzheimer\'s disease.[23](#acn3625-bib-0023){ref-type="ref"} Also, retigabine is in trials for treatment of amyotrophic lateral sclerosis (Clinicaltrial.gov ID: NCT02450552). A case report on one case treated with flupirtine in NCL disease is published.[24](#acn3625-bib-0024){ref-type="ref"}

Retigabine, benzyl‐derivatized carbamate (compound 5) and allyl carbamate derivative (compound 6) possess neuroprotective activity in etoposide‐induced PC12 cells due to blunting of *CLN3* expression (Fig. [1](#acn3625-fig-0001){ref-type="fig"}A). Etoposide increases apoptosis in neuronal precursor PC12 cells, and flupirtine affords statistically significant protection to cells. Blocking *CLN3* expression in cells provides a good in vitro model for CLN3 disease. In patient‐derived lymphoblasts, the neuroprotective effect of flupirtine/retigabine and novel aromatic carbamates was drug‐dose, and disease‐specific. Patient lymphoblasts provide a peripheral tissue for testing of NCL variants. Prevention of apoptosis in lymphoblasts constitutes a surrogate marker for testing therapeutic agents with potential neuroprotective activity in the brain. The concentrations of the compounds used in this study were based on the concentration of flupirtine (20 *μ*mol/L) already in use in the literature proven to be neuroprotective in vitro in several cell models.[14](#acn3625-bib-0014){ref-type="ref"} An important question arises whether drug concentrations with which we observed neuroprotective effects in vitro correlate with concentrations of flupirtine used in humans.[25](#acn3625-bib-0025){ref-type="ref"} In fact, plasma concentrations of flupirtine required for analgesic activity in humans correlates with in vitro concentrations of 2.5--6.5 *μ*mol/L.

Ceramide is involved in apoptosis and cell death. Elevated ceramide levels are documented in CLN2/3 disease patients and in *Cln3‐*knockout mouse brains, contributing to accelerated apoptosis.[6](#acn3625-bib-0006){ref-type="ref"}, [26](#acn3625-bib-0026){ref-type="ref"} Wild‐type CLN3p downregulates ceramide and has significant anti‐apoptotic activity (Fig. [7](#acn3625-fig-0007){ref-type="fig"}).[9](#acn3625-bib-0009){ref-type="ref"} Ceramide accumulates in CLN3‐deficient cells with CLN3 transfection restoring levels to normal.[4](#acn3625-bib-0004){ref-type="ref"}, [6](#acn3625-bib-0006){ref-type="ref"}, [9](#acn3625-bib-0009){ref-type="ref"}, [27](#acn3625-bib-0027){ref-type="ref"} Baseline levels of ceramide in CLN1/2/3/6/8‐derived lymphoblast cells were significantly higher than in normal lymphoblasts. Treatment with flupirtine, benzyl‐derivatized carbamate (compound 5) or allyl carbamate derivative (compound 6) decreased ceramide in a compound and NCL disease‐specific manner. The actions of these drugs could be acting upstream of ceramide generation on one or more of the de novo ceramide pathway enzymes such as ceramide synthases 2 and 6 (CERS2 and 6), dihydroceramide desaturase 2 (DEGS2), or acid sphingomyelinase phosphodiesterase 1 (SMPD1) (Fig. [7](#acn3625-fig-0007){ref-type="fig"}).

![Schematic representation of the effects of CLN3, flupirtine, retigabine, and benzyl (compound 5) or allyl (compound 6) carbamate derivatives on ceramide synthesis and intrinsic/extrinsic apoptotic pathways. Schematic representation of sphingolipid synthetic pathways and apoptotic events. The sites of action of the various sphingolipid synthesis enzymes and the location of the CLN3 action are indicated. Enzymes downregulated are shown in pink. Apoptosis extrinsic and intrinsic pathways are indicated. Each requires specific triggering signals to begin an energy‐dependent cascade of molecular events. Each pathway activates its own initiator caspase (caspase 8 or 9), which in turn activates executioner caspase 3. The execution pathway results in cell shrinkage, chromatin condensation, formation of cytoplasmic blebs and apoptotic bodies and ultimate phagocytosis of apoptotic bodies by adjacent parenchymal cells, neoplastic cells, or macrophages. Arrows indicate activation. Red T bar indicates inhibition. CLN3: Ceroid Lipofuscinosis, Neuronal 3; CERS2: Ceramide Synthase 2; CERS6: Ceramide Synthase 6; DEGS2: Delta 4‐Desaturase, Sphingolipid 2; SMPD1: Sphingomyelin Phosphodiesterase 1. FADD:FAS‐associated death domain; BAK: Bcl‐2 antagonist/killer‐1; BAX:BCL‐2‐associated X protein; BCL‐2: B‐cell lymphoma 2.](ACN3-5-1089-g007){#acn3625-fig-0007}

Flupirtine imparts its anti‐apoptotic effect by upregulating *BCL‐2*.[14](#acn3625-bib-0014){ref-type="ref"} The BCL‐2 family encodes proteins that regulate apoptosis including pro‐apoptotic BAX and BAK, anti‐apoptotic BCL‐2 and Bcl‐xL, and others. BAX and BCL‐2 are present in the mitochondrial membrane and maintain balance between cell survival and death by regulating cytochrome c release and activation of the caspase cascade and apoptosis (Fig. [7](#acn3625-fig-0007){ref-type="fig"}).[28](#acn3625-bib-0028){ref-type="ref"}, [29](#acn3625-bib-0029){ref-type="ref"} Blocking *CLN3* expression decreased expression of *BCL‐2* mRNA. Flupirtine/carbamate derivatives 5 and 6 reversed *BCL‐2* downregulation.

Apoptosis and autophagy are interdependent contributors to cell death, with caspases initiating the process that is well‐documented in CLN3 patient cells.[3](#acn3625-bib-0003){ref-type="ref"} Inhibition of *BCL‐2* expression, release of cytochrome c, and activation of caspases 3/8/9 result in an apoptotic cascade. Caspase‐dependent extrinsic apoptosis is launched via the death receptor pathway, which activates initiator caspase 8, then effector caspase 3. The intrinsic pathway is activated from mitochondria by cell signals via initiator caspase 9, then effector caspase 3[30](#acn3625-bib-0030){ref-type="ref"} (Fig. [7](#acn3625-fig-0007){ref-type="fig"}). Caspase 3 increased expression is a marker for apoptosis.[31](#acn3625-bib-0031){ref-type="ref"} Involvement of caspase 8 is documented in apoptotic pathways in neurodegenerative diseases.[3](#acn3625-bib-0003){ref-type="ref"}, [32](#acn3625-bib-0032){ref-type="ref"} *Caspase 8* upregulation is indispensable for the signal transduction cascade via the extrinsic apoptotic pathway (Fig. [7](#acn3625-fig-0007){ref-type="fig"}).[30](#acn3625-bib-0030){ref-type="ref"} Caspase 9 is activated by release of cytochrome c from damaged mitochondria through interaction with APAF‐1 followed by activation of caspase 3.[33](#acn3625-bib-0033){ref-type="ref"} Caspase 3 then cleaves poly (ADP‐ribose) polymerase‐1 (PARP‐1) involved in DNA damage inducing programmed cell death (Fig. [7](#acn3625-fig-0007){ref-type="fig"}).[34](#acn3625-bib-0034){ref-type="ref"} Elevated *Caspases 3/8/9* expression is consistent with increase in number of J‐aggregates by JC‐1 staining, following blocking of *CLN3* expression. Flupirtine effectively downregulated expression of *Caspases 3/8/9*, and decreased the apoptotic cell count. Similarly, benzyl‐derivatized carbamate (compound 5) significantly downregulated expression of *Caspases 3/8/9*. Allyl carbamate derivative (compound 6) downregulated expression of *Caspases 3/8*, keeping *Caspase 9* expression intact. These findings imply that flupirtine and compound 5 act via the extrinsic/intrinsic pathways, whereas compound 6 exerts its effect only via the extrinsic pathway.

BCL‐2 protein (BCL‐2p) inhibits ceramide channel formation in the outer mitochondrial membrane[35](#acn3625-bib-0035){ref-type="ref"} in vitro. Ghafourifar et al. demonstrate that anti‐apoptosis by BCL‐2p is exerted downstream of ceramide since pre‐incubation with BCL‐2p prevents ceramide‐induced cytochrome c release in mitochondria.[36](#acn3625-bib-0036){ref-type="ref"} Other groups report that *BCL‐2* overexpression rescues from ceramide‐induced apoptosis[37](#acn3625-bib-0037){ref-type="ref"}, [38](#acn3625-bib-0038){ref-type="ref"} or ceramidase inhibitor‐induced apoptosis.[39](#acn3625-bib-0039){ref-type="ref"} While BCL‐2p acts downstream of ceramide, Bcl‐xL targets the ceramide pathway inhibiting ceramide generation, acting upstream of ceramide.[40](#acn3625-bib-0040){ref-type="ref"} Other studies demonstrate that ceramide accumulation after DNA damage can be reduced by *BCL‐2* or *Bcl‐xL* overexpression, suggesting an upstream action of both proteins.[41](#acn3625-bib-0041){ref-type="ref"}, [42](#acn3625-bib-0042){ref-type="ref"}, [43](#acn3625-bib-0043){ref-type="ref"} This highlights importance of the BCL‐2 family in initiation and regulation of the ceramide pathway (Fig. [7](#acn3625-fig-0007){ref-type="fig"}). Puranam et al. established that transfection of CLN3‐derived cells with CLN3 cDNA corrects apoptosis and lowers ceramide back to normal.[9](#acn3625-bib-0009){ref-type="ref"} CLN3p, which resides in the membrane, fine‐tune regulation of the apoptotic pathway by attenuating ceramide generation. Also, ceramide accumulation occurs upstream of caspase activation[44](#acn3625-bib-0044){ref-type="ref"} induces caspase‐dependent apoptosis, unlike BCL‐2p, which acts downstream of ceramide, but upstream of caspase 3. CLN3 protein modulates the generation of ceramide which occurs upstream of BCL‐2p and caspase activation in CLN3‐derived cells.

Ceramide formation or breakdown in the cell has at least 5 known origins: (1) sphingomyelin hydrolysis via neutral/acid sphingomyelinase (SMPD); (2) breakdown to sphingosine by ceramidase; (3) de novo synthesis of ceramide by ceramide synthases (CerS); (4) generation of cerebrosides via cerebroside synthase; and (5) formation of ceramide phosphate by ceramide kinase.[9](#acn3625-bib-0009){ref-type="ref"}, [45](#acn3625-bib-0045){ref-type="ref"} Upregulation of ceramide de novo synthesis enzymes (CERS2, CERS6, and DEGS2) and ceramide hydrolytic enzyme (SMPD1) was observed in CLN3‐derived PC12 cells, in line with the increase in ceramide levels. Downregulation of *CERS2/CERS6/SMPD1/DEGS2* in neuronal precursor PC12 cells treated with flupirtine/compounds 5 or 6 reflects the impact of these aromatic carbamate derivatives on ceramide synthesis. They are specifically involved in de novo ceramide synthesis (CERS2/CERS6/DEGS2), and synthesis of ceramide from sphingosine (CERS2/CERS6), and degradation of sphingomyelin (SMPD1) to ceramide (Fig. [7](#acn3625-fig-0007){ref-type="fig"}). Alterations in these enzymes may affect the pathophysiology of various forms of NCL disease and shed light on the mechanism of action of these novel carbamates.

Dihydroceramide synthases (CERS2/CERS6) acylate sphinganine and sphingosine to form dihydroceramide and ceramide, respectively. Higher levels of dihydroceramide synthases may directly/indirectly lead to increased ceramide in neuronal tissue accelerating neurodegeneration. DEGS2 is responsible for conversion of dihydroceramides generated via de novo synthesis to ceramide.[46](#acn3625-bib-0046){ref-type="ref"} Blocking DEGS2 leads to decreased cell proliferation and cell cycle arrest.[47](#acn3625-bib-0047){ref-type="ref"} The fourth enzyme, SMPD1, or acid sphingomyelinase (SMase) catalyzes hydrolysis of sphingomyelin to ceramide and phosphocholine. Several SMases have been identified[48](#acn3625-bib-0048){ref-type="ref"} and are upregulated in tumor tissue, but correlation with neurodegeneration is not established yet.[49](#acn3625-bib-0049){ref-type="ref"} The significant downregulation in ceramide pathway enzyme expression after treatment with flupirtine/compounds 5/6 are consistent with the observed reduction in ceramide levels. Ceramide participation has proven central to many neurodegenerative diseases. Neurodegenerative disorders are marked by extensive neuronal apoptosis and gliosis. Regulatory mechanisms of cell death are not fully elucidated. Understanding cell death mechanisms is enhanced by exploring impact of compounds on the ceramide synthetic pathway. The clarification of flupirtine and other aromatic carbamate derivatives' impact on this pathway add to an emerging field of therapeutically significant drugs impacting ceramide regulation potentially effective in treating neurodegenerative disorders.[50](#acn3625-bib-0050){ref-type="ref"}, [51](#acn3625-bib-0051){ref-type="ref"}

There were differences noted in effects of flupirtine, the benzyl or the allyl carbamate derivative on cell growth, apoptosis, ceramide levels, and mRNA expression levels of caspases or sphingolipid metabolism enzymes. In fact, the differences documented in cell models for NCL disease variants could suggest that differences in magnitude and/or mechanisms may be at play in the neuroprotective effects observed for flupirtine or the different aromatic carbamate derivatives that are NCL disease variant specific.

In conclusion, allyl carbamate derivative (compound 6) possesses greater anti‐apoptotic activity than flupirtine in neuronal precursor PC12 cells and in CLN1/2/3/6/8 patient lymphoblasts. These experiments serve as preclinical assays for potential use of these aromatic carbamate derivatives to treat CLN3 disease and these CLN1/2/6/8 diseases in animal models and humans. Alteration in BCL‐2/ceramide synthesis enzyme expression levels support that flupirtine analogues impact the ceramide synthesis pathway. Future experiments in *Cln3* ^*Δex7/8*^ knock‐in mice/CLN2/*Cln6* ^*nclf*^/CLN8‐derived mouse models will shed further light on the role of aromatic carbamate derivatives of flupirtine in treatment of NCL disease variants.
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